The accelerated approval is part of the FDA’s Project FrontRunner, aimed at advancing cancer drug development.

In a new study, researchers from Melbourne's Peter MacCallum Cancer Center demonstrated that it was possible to use the ...

Peter Mac scientists have found a way to use the powerful gene editing tool CRISPR to silence cancer-causing gene mutations ...

for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA-approved test. i The indication was approved based on a statistically ...

Patients with the BRAF V600E mutation and metastatic colorectal cancer (CRC) can be treated with a combination of encorafenib with cetuximab and mFOLFOX6. Patients were eligible for the study if ...

With today’s accelerated approval of the BRAFTOVI regimen, patients with metastatic colorectal cancer with a BRAF V600E mutation now have a first-line treatment option, which contains a targeted ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) in combination with ...

19 (Xinhua) -- Australian researchers have found a way to silence cancer-causing gene ... CRISPR to silence the gene mutations KRAS G12, NRAS G12D, and BRAF V600E that drive aggressive pancreatic ...

U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer ...

(NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI ® (encorafenib) in combination with cetuximab (marketed as ERBITUX ®) and mFOLFOX6 (fluorouracil, ...